LIFEMD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.71 USD | -2.41% |
|
-15.09% | -7.00% |
| May. 09 | Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating | MT |
| May. 08 | Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6.082 | 137.1 | 118.4 | 61.01 | 325 | 326.1 | - |
| Enterprise Value (EV) 1 | 6.082 | 137.1 | 77.74 | 61.01 | 325 | 326.1 | 326.1 |
| P/E ratio | -1.64 x | -1.47 x | -1.69 x | -1.24 x | -11.8 x | -28.8 x | 58.4 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 1.58 x | 1.28 x |
| EV / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 1.58 x | 1.28 x |
| EV / EBITDA | - | -8.43 x | -3.09 x | -4.16 x | 27.1 x | 16.7 x | 10.7 x |
| EV / FCF | - | -11.3 x | -3.25 x | - | - | 34.5 x | 23.1 x |
| FCF Yield | - | -8.85% | -30.8% | - | - | 2.9% | 4.33% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 10,578 | 20,992 | 30,593 | 31,450 | 39,203 | 42,290 | - |
| Reference price 2 | 0.5750 | 6.530 | 3.870 | 1.940 | 8.290 | 7.710 | 7.710 |
| Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 37.29 | 92.88 | 119 | 152.5 | 206.1 | 254.1 |
| EBITDA 1 | - | -16.26 | -38.28 | -14.66 | 11.98 | 19.52 | 30.43 |
| EBIT 1 | - | -57.82 | -54.3 | -43.45 | -14.49 | -4.856 | 12.79 |
| Operating Margin | - | -155.04% | -58.47% | -36.5% | -9.5% | -2.36% | 5.03% |
| Earnings before Tax (EBT) 1 | - | -60.4 | -61.32 | -44.66 | -17.41 | -7.013 | 10.55 |
| Net income 1 | -3.137 | -63.36 | -61.77 | -48.64 | -23.7 | -11.33 | 5.983 |
| Net margin | - | -169.9% | -66.51% | -40.86% | -15.54% | -5.5% | 2.35% |
| EPS 2 | -0.3500 | -4.440 | -2.290 | -1.570 | -0.7000 | -0.2675 | 0.1320 |
| Free Cash Flow 1 | - | -12.13 | -36.47 | - | - | 9.453 | 14.11 |
| FCF margin | - | -32.53% | -39.26% | - | - | 4.59% | 5.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 48.44% | 46.37% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 235.85% |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 27.42 | 29.04 | 30.46 | 31.41 | 28.12 | 33.13 | 35.95 | 38.61 | 44.86 | 44.14 | 47.99 | 52.81 | 60.24 | 55.15 | 58.96 |
| EBITDA 1 | -8.219 | -7.584 | -6.927 | -1 | 0.6307 | 2 | 1.733 | 2.775 | 5.489 | 0.4468 | 2.539 | 6.015 | 10.51 | 4.391 | 5.698 |
| EBIT 1 | -13.66 | -13.11 | -15.64 | -6.818 | -10.37 | -2.853 | -4.896 | -4.569 | -2.172 | -6.171 | -3.064 | 0.0094 | 4.049 | -2.69 | -0.8875 |
| Operating Margin | -49.84% | -45.13% | -51.35% | -21.7% | -36.88% | -8.61% | -13.62% | -11.83% | -4.84% | -13.98% | -6.39% | 0.02% | 6.72% | -4.88% | -1.51% |
| Earnings before Tax (EBT) 1 | -18 | -13.27 | -12.97 | -7.198 | -11.21 | -3.442 | -5.891 | -5.283 | -2.794 | -6.649 | -3.63 | -0.5436 | 3.506 | -3.35 | -1.548 |
| Net income 1 | -18.98 | -14.08 | -13.8 | -8.058 | -12.71 | -4.785 | -7.51 | -6.899 | -4.509 | -7.545 | -4.853 | -1.651 | 2.495 | -4.782 | -2.98 |
| Net margin | -69.24% | -48.47% | -45.29% | -25.65% | -45.21% | -14.44% | -20.89% | -17.87% | -10.05% | -17.09% | -10.11% | -3.13% | 4.14% | -8.67% | -5.05% |
| EPS 2 | -0.6300 | -0.4600 | -0.4500 | -0.2600 | -0.4000 | -0.1500 | -0.2300 | -0.2000 | -0.1200 | -0.1900 | -0.1260 | -0.0420 | 0.0620 | -0.0700 | -0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/7/22 | 5/13/22 | 8/11/22 | 11/10/22 | 3/22/23 | 5/12/23 | 8/9/23 | 11/8/23 | 3/11/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | 40.7 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -12.1 | -36.5 | - | - | 9.45 | 14.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 3.38 | - | - | 0.5 | 0.44 |
| Capex / Sales | - | - | 3.64% | - | - | 0.24% | 0.17% |
| Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.71
USD
Average target price
13
USD
Spread / Average Target
+68.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.00% | 326M | |
| +19.82% | 7.85B | |
| +31.81% | 4.28B | |
| -30.43% | 2.64B | |
| -15.20% | 1.47B | |
| -26.60% | 1.3B | |
| -34.43% | 1.14B | |
| +10.41% | 987M | |
| -35.57% | 901M | |
| -21.81% | 696M |
- Stock Market
- Equities
- LFMD Stock
- Financials LifeMD, Inc.